|
PAION AG / Key word(s): Insolvency PAION AG: Filing an application for the opening of insolvency proceedings 26-Oct-2023 / 12:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. PAION AG: Filing an application for the opening of insolvency proceedings Aachen (Germany), 26 October 2023 – The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that it will immediately file for insolvency proceedings. The background to the filing is the fact that irregularities have come to light in the area of responsibility of the company’s CFO with regard to a financing that is important for the company. The exact background to this is currently being investigated. As a result of the irregularities, the company is obliged to file for insolvency. The Supervisory Board decided today to remove Mr Sebastian Werner, the member of the Executive Board responsible for financing and CFO, as a member of the Executive Board with immediate effect. In view of the current developments, the current capital increase with subscription rights will be cancelled and not carried out.
End of Inside Information Information and Explanation of the Issuer to this announcement: Contact Ralf Penner SVP Investor Relations & Corporate Communications PAION AG Heussstrasse 25 52078 Aachen – Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com 26-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Opinion | The Goldilocks Dilemma: Too Much, Too Little, Just Right
Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director
September 10, 2024